Table 2.
Characteristics of v-safe respondents submitting free-text responses related to menstrual irregularities or vaginal bleeding, by response theme*
| Timing | Severity | Menopausal | Resumption of menses | Other | Total | p value† | χ2 statistic | ||
|---|---|---|---|---|---|---|---|---|---|
| Number of unique respondents | 54 671 | 44 785 | 2912 | 2181 | 2625 | 63 815 | .. | .. | |
| Median age, years (IQR) | 37 (30–43) | 37 (31–44) | 54 (50–62) | 47 (37–53) | 37 (31–43) | 37 (30–44) | .. | .. | |
| Number of responses submitted | 70 981 | 56 890 | 3439 | 2378 | 2751 | 84 943 | .. | .. | |
| Vaccine received‡ | .. | .. | .. | .. | .. | .. | 0·016 | 19·11 | |
| BNT162b2 | 28 408 (52·0%) | 23 208 (51·8%) | 1425 (48·9%) | 1106 (50·7%) | 1399 (53·3%) | 33 149 (51·9%) | .. | .. | |
| mRNA-1273 | 22 937 (42·0%) | 18 757 (41·9%) | 1301 (44·7%) | 926 (42·5%) | 1056 (40·2%) | 26 741 (48·9%) | .. | .. | |
| Ad26.COV2.S | 3449 (6·3%) | 2905 (6·5%) | 186 (6·4%) | 151 (6·9%) | 170 (6·5%) | 4072 (6·4%) | .. | .. | |
| Other/unknown | 3 (<0·1%) | 3 (<0·1%) | 1 (<0·1%) | 0 | 0 | 3 (<0·1%) | .. | .. | |
| Respondents submitting responses ≤21 days after a dose | n=32 813 | n=27 363 | n=1324 | n=1234 | n=1397 | n=37 458 | .. | .. | |
| Dose 1 | 13 963 (42·6%) | 11 811 (43·2%) | 519 (39·2%) | 503 (40·8%) | 627 (44·9%) | 16 168 (43·2%) | 0·00020 | 31·41 | |
| Dose 2 | 17 835 (54·4%) | 14 700 (53·7%) | 711 (53·7%) | 679 (55·0%) | 685 (49·0%) | 20 383 (54·4%) | 0·045 | 10·09 | |
| Dose 3 | 2637 (8·0%) | 2184 (8·0%) | 126 (9·5%) | 66 (5·3%) | 93 (6·7%) | 2996 (8·0%) | 0·0024 | 16·96 | |
| Ever reported any solicited injection site reaction§¶ | 46 443/51 259 (90·6%) | 38 145/41 906 (91·0%) | 2374/2726 (87·1%) | 1797/2030 (88·5%) | 2224/2455 (90·6%) | 54 193/59 790 (90·6%) | 0·00020 | 78·69 | |
| Ever reported any solicited systemic reaction§‖ | 46 659/51 259 (91·0%) | 38 444/41 906 (91·7%) | 2390/2726 (87·7%) | 1811/2030 (89·2%) | 2272/2455 (92·5%) | 54 477/59 790 (91·1%) | 0·00020 | 122·10 | |
| Reported seeking health care on the same survey | 9062 (16·6%) | 6920 (15·5%) | 1090 (37·4%) | 386 (17·7%) | 366 (13·9%) | 10 711 (16·8%) | 0·00020 | 1109·42 | |
Data are n, median (IQR), n (%), and n/N (%) unless specified otherwise.
Proportions reported out of the number of respondents.
Bootstrap p values test independence between each respondent characteristic and theme under models for multiple response categorical variables (MRCV).
Respondents reporting multiple doses might have received more than one vaccine type.
Among recipients of BNT162b2 or mRNA-1273 vaccines.
Injection site reactions include pain, redness, swelling, or itching reported ≤7 days after a dose.
Systemic reactions include fatigue, headache, myalgia, chills, fever, joint pain, nausea, vomiting, diarrhoea, abdominal pain, or rash outside of injection site reported ≤7 days after a dose.